POTENTIALS FOR THE OPTIMIZING THE CONTROL OF BRONCHIAL ASTHMA: SMALL AIRWAYS AND EXTRA-FINE-DISPERSED FORMS OF INHALERS


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Clinical practice shows that adequate control of bronchial asthma (BA) is absent in more than 50% of patients. The cause of unsatisfactory BA control may be insufficient suppression of inflammation in the respiratory tract, including distal airways. Inhalation therapy remains the leading method of treatment of BA. One of the important properties of the inhaled medication, which determines the severity of its anti-inflammatory and bronchodilating action, is the level of deposition in the airways. To achieve small airways, «responsible» for an insufficient level of control in certain BA phenotypes, it is necessary to use drugs, including combined drugs, containing extrafine dispersed aerosol forms. During the last decade, a significant database on the positive effects of beclomethasone dipropionate/ formoterol (BDP/F) on everyday BA symptoms, respiratory function, and the frequency of exacerbations has been accumulated. Currently, the evaluation of the effectiveness of BDP/F continues primarily in those groups of patients with asthma, where the impact of the pathology of small airways can adversely affect the ability to achieve control: in smokers, in patients with a long history of asthma, in patients with detected «air trapping» phenomenon. BDP/F provides the most significant effect, incl. pronounced reducing the frequency of exacerbations, specifically in such patients.

Толық мәтін

Рұқсат жабық

Авторлар туралы

A. Sinopalnikov

Russian Medical Academy of Continuous Professional Education

Yu. Belotserkovskaya

Russian Medical Academy of Continuous Professional Education

Email: belo-yuliya@yandex.ru
PhD, Associate Professor at the Department of Pulmonology

A. Romanovsky

Russian Medical Academy of Continuous Professional Education

Әдебиет тізімі

  1. To T., Stanojevic S., Moores G., et al. Global asthma prevalence in adults: findings from the crosssectional world health survey. BMC Public Health. 2012;12:204. doi: 10.1186/1471-2458-12-204.
  2. Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469-78.
  3. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2095-128. doi: 10.1016/S0140-6736(12)61728-0.
  4. Vos T, Flaxman A.D., Naghavi M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-96. doi: 10.1016/S0140-6736(12)61729-2.
  5. Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21(123):66-74. doi: 10.1183/09059180.00008111.
  6. Demoly P., Gueron B., Annunziata K., et al. Update on asthma control in five European countries: results of a 2008 survey Eur Respir Rev. 2010;19( 116):150e7. doi: 10.1183/09059180.00002110.
  7. Hodder R. The paradox of adult asthma control: «Who's in control anyway?». Can Respir J. 2007;14(4):229-34.
  8. Suzuki T., Saito I., Adachi M., et al. Influence of patients' adherence to medication, patient background and physicians' compliance to the guidelines on asthma control. Yakugaku Zasshi. 2011;131(1):129-38.
  9. GINA Report. Global Strategy for Asthma Management and Prevention. Updated 2017. The GINA reports are available on www.ginasthma.org
  10. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. 2016.
  11. Bateman E.D., Boushey H.A., Bousquet J., et al. Canguideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med. 2004;170(8):836-44.
  12. Sheehan W.J., Phipatanakul W. Difficult to Control Asthma: Epidemiology and its Link with Environmental Factors. Curr Opin Allergy Clin Immunol. 2015;15(5):397-401. Doi: 10.1097/ ACI.0000000000000195.
  13. Spallarossa D., Battistini E., Silvestri M., et al. Steroid-naive adolescents with mild intermittent allergic asthma have airway hyperresponsiveness and elevated exhaled nitric oxide levels. J Asthma. 2003;40:301-10.
  14. Contoli M., Kraft M., Hamid Q., et al. Do small airway abnormalities characterize asthma phenotypes? In search of proof. Clinical & Experimental Allergy. 2012;42:1150-60. doi: 10.1111/j.1365-2222.2012.03963.x.
  15. Kobrich R., Rudolf G., Stahlhofen W. A mathematical model of mass deposition in man. Ann Occup Hyg. 1994;38:15-23.
  16. Pauwels R., Newman S., Borgstrom L. Airway deposition and the airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J. 1997;10:2127-38.
  17. Laube B.L., Janssens H.M., de Jongh F.H.C., et ai. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308-31. doi: 10.1183/09031936.00166410.
  18. Hendeles L., Colice G.L., Meyer R.J. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N Engl J Med. 2007;356:1344-51.
  19. Thorsson L., Edsbacker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. fur Respir J. 1998;12:1340-45.
  20. Ganderton D. Targeted delivery of inhaled drugs: current challenges and future goal. J Aerosol Med. 1999;12(1):3-8.
  21. Scichilone N., Spatofora M., Battaglia S., et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. Journal of Asthma and Allergy. 2013;6:11-21. doi: 10.2147/JAA.S14743.
  22. Leach C.L., Kuehl P.J., Chand R., et al. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol. 2012;108(3):195-200. doi: 10.1016/j.anai.2012.01.010.
  23. Mariotti F., Poli G., Acerbi D., et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic and COPD patients [abstract]. Poster presented at the VIII UIP National congress, Florence. 4-7 December 2007.
  24. Scichilone N., Battaglia S., Sorino C., et al. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy. 2010;65(7):897-902. doi: 10.1111/j.1398-9995.2009.02306.x.
  25. GINA Report. Global Strategy for Asthma Management and Prevention. Updated 2018. The GINA reports are available on www.ginasthma.org
  26. Goldin J.G., Tashkin D.P., Kleerup E.C., et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipro- pionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol. 1999;104(6):258-67.
  27. Papi A., Paggiaro P., Nicolini G., et al. Beclomethasone/ formoterol vs fluticasone/ salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007;62(10):1182-88.
  28. Huchon G., Magnussen H., Chuchalin A., et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med. 2009;103(1): 41-9. Doi: 10.1016/j. rmed.2008.09.002.
  29. Muller V., Galffy G., Eszes N., et al. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extra-fine formulation. BMC Pulm Med. 2011;11:40.
  30. Allegra L., Cremonesi G., Girbino G., et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med. 2012; 106(2):205-14. Doi: 10.1016/j. rmed.2011.10.001.
  31. Papi A., Corradi M., Pigeon-Francisco C., et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomized controlled trial. Lancet respire Med. 2013;1:23-31. Doi: 10.1016/ S2213-2600(13)70012-2.
  32. Marth K., Spinola M., Kisiel J., et al. Treatment response according to small airway phenotypes: a real-life observational study. Ther Adv Respir Dis. 2016;10(3):200-10. doi: 10.1177/1753465816642635.
  33. Hsieh M.J., Lin Y.C., Lai R.S., et al. Comparative efficacy and tolerability of beclomethasone/ formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients. J Formos Med Assoc. 2017;pii: S0929- 6646(17)30549-1. Doi: 10.1016/j. jfma.2017.12.005.
  34. Morjaria J.B., Rigby A.S., Morice A.H. Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma? Eur Respir J. 2017;50:1701366. doi: 10.1183/13993003.01366-2017.
  35. Terzano С., Cremonesi G., Girbino G., et al. 1-year prospective real life monitoring of asthma control and quality of life in Italy. Respiratory Research. 2012, 13:112-23.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>